本刊讯全世界超过3000万人受“老年性黄斑退化症”(AMD)影响,这是老年人致盲的主要原因。这种疾病的新生血管致盲形式的标准治疗方法是采用抗VEGF药物——主要是“雷珠单抗”(Lucentis)和“贝伐珠单抗”(Avastin),但它们只能让三分之一患者改善视力,而且人们对可能产生的毒性也有担心,因为VEGF在正常视网膜功能中发挥了重要作用。 More than 30 million people in the world are affected by AMD, which is the leading cause of blindness in the elderly. The standard treatment for the neovascular form of this disease is the use of anti-VEGF drugs - predominately “Lucentis” and “Avastin” but they only One third of patients can improve vision, and people are also worried about the potential toxicity because VEGF plays an important role in normal retinal function.